Aktuellt
SENASTE
Redeye notes that Heliospectra’s Q2 numbers are on par with Q1 and mainly in line with our expectations. The market climate still appears to be somewhat hesitant, but we are quite certain the company will show growing sales over the next couple of years. The underlying demand for Heliospectras solutions will increase substantially for decades to come. A stronger sales organization and improved offering, including the launch of biosensor systems in 2022, will in our view give excellent growth opportunities. We are trimming our short-term estimates somewhat but are still confident in our long-term positive view.
LÄS MER
